These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21324922)

  • 1. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.
    Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE
    Cancer Res; 2011 Apr; 71(7):2706-17. PubMed ID: 21324922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.
    Yuan W; Stawiski E; Janakiraman V; Chan E; Durinck S; Edgar KA; Kljavin NM; Rivers CS; Gnad F; Roose-Girma M; Haverty PM; Fedorowicz G; Heldens S; Soriano RH; Zhang Z; Wallin JJ; Johnson L; Merchant M; Modrusan Z; Stern HM; Seshagiri S
    Oncogene; 2013 Jan; 32(3):318-26. PubMed ID: 22370636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.
    Tikoo A; Roh V; Montgomery KG; Ivetac I; Waring P; Pelzer R; Hare L; Shackleton M; Humbert P; Phillips WA
    PLoS One; 2012; 7(5):e36924. PubMed ID: 22666336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis.
    Yuan W; Goldstein LD; Durinck S; Chen YJ; Nguyen TT; Kljavin NM; Sokol ES; Stawiski EW; Haley B; Ziai J; Modrusan Z; Seshagiri S
    Breast Cancer Res; 2019 Dec; 21(1):152. PubMed ID: 31881983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
    Meyer DS; Brinkhaus H; Müller U; Müller M; Cardiff RD; Bentires-Alj M
    Cancer Res; 2011 Jul; 71(13):4344-51. PubMed ID: 21482677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common and distinct features of mammary tumors driven by Pten-deletion or activating Pik3ca mutation.
    Liu JC; Wang DY; Egan SE; Zacksenhaus E
    Oncotarget; 2016 Feb; 7(8):9060-8. PubMed ID: 26814435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of wildtype RhoC promotes ErbB2- and Pik3ca-induced mammary tumor formation.
    Raghuram N; Temel EI; Kawamata T; Kozma KJ; Loch AJ; Wang W; Adams JR; Muller WJ; Egan SE
    Breast Cancer Res; 2024 May; 26(1):86. PubMed ID: 38807216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.
    Koren S; Bentires-Alj M
    FEBS J; 2013 Jun; 280(12):2758-65. PubMed ID: 23384338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Sep; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
    Liu P; Cheng H; Santiago S; Raeder M; Zhang F; Isabella A; Yang J; Semaan DJ; Chen C; Fox EA; Gray NS; Monahan J; Schlegel R; Beroukhim R; Mills GB; Zhao JJ
    Nat Med; 2011 Aug; 17(9):1116-20. PubMed ID: 21822287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
    Hanker AB; Pfefferle AD; Balko JM; Kuba MG; Young CD; Sánchez V; Sutton CR; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Proc Natl Acad Sci U S A; 2013 Aug; 110(35):14372-7. PubMed ID: 23940356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects.
    Hare LM; Schwarz Q; Wiszniak S; Gurung R; Montgomery KG; Mitchell CA; Phillips WA
    Dev Biol; 2015 Aug; 404(1):14-26. PubMed ID: 25958091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
    Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
    Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.
    Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J
    Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urothelium-Specific Expression of Mutationally Activated Pik3ca Initiates Early Lesions of Noninvasive Bladder Cancer.
    Shuman L; Pham J; Wildermuth T; Wu XR; Walter V; Warrick JI; DeGraff DJ
    Am J Pathol; 2023 Dec; 193(12):2133-2143. PubMed ID: 37544503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
    Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
    Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.
    Blanco-Aparicio C; Cañamero M; Cecilia Y; Pequeño B; Renner O; Ferrer I; Carnero A
    PLoS One; 2010 Feb; 5(2):e9305. PubMed ID: 20174572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.